The U.S. will begin sharing its entire stock of AstraZeneca COVID-19 vaccines with the world once it clears federal safety reviews, the White House said Monday, with as many as 60 million doses expected to be available for export in the coming months.

The move greatly expands on the Biden administration’s action last month to share about 4 million doses of the vaccine with Mexico and Canada. The AstraZeneca vaccine is widely in use around the world but has not yet been authorized by the U.S. Food and Drug Administration.

The White House is increasingly feeling assured about the supply of the three vaccines being administered in the U.S., particularly following the restart of the single-dose Johnson & Johnson shot over the weekend. The U.S. has also been under mounting pressure in recent weeks to share more of its vaccine supply with the world, as countries like India experience devastating surges of the virus and others struggle to access doses needed to protect their most vulnerable populations.

“Given the strong portfolio of vaccines that the U.S. already has and that have been authorized by the FDA, and given that the AstraZeneca vaccine is not authorized for use in the U.S., we do not need to use the AstraZeneca vaccine here during the next several months,” said White House COVID-19 coordinator Jeff Zients. “Therefore the U.S. is looking at options to share the AstraZeneca doses with other countries as they become available.”

More than 3 million people worldwide have died of COVID-19, including more than 572,000 in the U.S. The U.S. has vaccinated more than 53% of its adult population with at least one dose of its three authorized vaccines from Pfizer, Moderna and J&J, and it expects to have enough supply for its entire population by early summer.

About 10 million doses of AstraZeneca vaccine have been produced but have yet to pass review by the FDA to “meet its expectations for product quality,” Zients said, noting the U.S. regulator is recognized as the “gold standard” for safety around the world. That process could be completed in the next several weeks. About 50 million more doses are in various stages of production and could be available to ship in May and June pending FDA sign-off.

The U.S. has yet to finalize where the AstraZeneca doses will go, Zients said. Neighbors Mexico and Canada have asked the Biden administration to share more doses, while dozens of other countries are looking to access supplies of the vaccine.

“We’re in the planning process at this point in time,” said White House press secretary Jen Psaki, when asked where the doses would go.

The AstraZeneca doses will be donated by the U.S. government, which has contracted with the company for a total of 300 million doses — though the company has faced production issues.

The administration’s move to share vaccines drew praise from nongovernmental aid groups, who encouraged the White House to develop plans to share even more doses.

“The Biden administration’s decision to begin sharing AstraZeneca vaccines is welcome news and an important first step towards the US sharing more of its massive vaccine stockpile,” said Tom Hart, acting CEO at The ONE Campaign. “The Biden administration should build on this welcome first step and start sharing more vaccines as soon as possible.”

In part because the AstraZeneca vaccine is not expected to play a significant factor in the U.S. virus response, the White House was also moving to share raw materials for the production of the AstraZeneca vaccine with India, which has emerged as a global hotspot for the virus, by diverting some of its orders to the vaccine manufacturer Serum Institute of India.

Zients told the AP that the Biden administration was working to satisfy other “key requests” from the Indian government, namely for personal protective equipment, tests, therapeutics and supplies of oxygen and respiratory assistance devices.

“The administration’s identified U.S. commercial suppliers of therapeutics that are immediately available to help relieve the suffering of the COVID-19 patients in India,” said Zients. “We’ve identified rapid diagnostic tests and supplies and PPE, and additional ventilators that are available to transferred to India.”

Epidemiologists from the Centers for Disease Control and Prevention were also expected to soon travel to India to assist the country with its virus response.

The additional quality review before the U.S. shares the AstraZeneca doses were in order because of issues at the facility that produced them, White House officials said.

AstraZeneca’s doses in the U.S. were produced at an Emergent BioSolutions plant in Baltimore that has come under increased regulatory and public scrutiny after botching batches of the J&J vaccine. The U.S. pressed J&J to take over the plant and, as part of the effort to ensure the quality of newly produced vaccines, directed the facility to stop making the AstraZeneca shot. AstraZeneca is still looking to identify a new U.S. production facility for its future doses.

The U.S. government ordered enough for 150 million Americans before issues with the vaccine’s clinical trial held up clearance. The company’s 30,000-person U.S. trial didn’t complete enrollment until January, and it still has not filed for an emergency-use authorization with the FDA.